Health insurance exchanges don?t have to be in place until 2014, but states are quickly gearing up for their launch. Dhan Shapurji, director, Deloitte Consulting, along with two of his colleagues, neatly packaged the challenges facing exchanges into nine operational components:
Health insurance exchanges don’t have to be in place until 2014, but states are quickly gearing up for their launch. Dhan Shapurji, director, Deloitte Consulting, along with two of his colleagues, neatly packaged the challenges facing exchanges into nine operational components:
“Each component has features that potentially affect current legacy operations or may require developing new capabilities and services to help address the needs of businesses on the exchange,” Shapurji said. For example, some plans are contemplating developing a limited network to present a low-cost option for the exchange.
Shapurji explored four major issues associated with the operational factors–channel disruption, financing and reconciliation, eligibility dynamics and the customer experience, the latter two affected by the growing number of persons who will enter the insurance pool.
“We know that health exchanges will be transformational, ” Shapurji said. “We anticipate seeing variability in models among states, which will need to offer different levels of benefits in order to create a competitive environment and keep premiums down. There are still many questions left on the table, from information interoperability to premiums and the delivery of services. ”
Shapurji foresees that state exchanges will look to HHS for guidance on how household income will be calculated and monitored for subsidy eligibility; who will undertake premium collection, reconciliation and determine disenrollment if the premium is not paid; and what mechanisms will be established to smoothly transfer customers between products and services.
He noted that plans also have to prepare themselves by determining which markets they are going to compete in and what type of competition they will face. Once they determine the scope of their markets, they can analyze the types of services and capabilities required to compete.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More